Diffuse Large B-Cell Lymphoma Unclassifiable — Variants & evidence

Diffuse Large B-Cell Lymphoma Unclassifiable — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items (1 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EZH2 expression1
Tazemetostat	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	Predictive	C	Supports Sensitivity Response	1	accepted	EID11108 In this phase I study (clinical trial NCT03009344), one patient with germinal center B‐cell‐like (GCB) DLBCL and two with non-GCB DLBCL types were recruited to test the efficacy of EZH2 inhibitor-Taze… (full text at CIViC) PMID 33492746 · Munakata et al., 2021 · Open in CIViC	civic

Data updated 21 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.